Review Papers Claim by Claim

Visualized claims (evidence‑linked)

• Accurate description of CRISPR origin & mechanism: authors cite Jinek et al. (2012) for programmable sgRNA‑guided Cas9 activity — foundational work establishing CRISPR‑Cas9 genome editing (Jinek et al. (2012)
• Examples cited (zygote, in‑vivo, ex‑vivo): the review summarizes mouse zygote editing (Wang et al. / Cell 2013), in vivo somatic correction (Yin et al. 2014), ex vivo iPSC/organoid corrections (Schwank et al., Xie et al.) — correct high‑level selection but no systematic coverage or date‑range explanation (Wang et al. (2013), Yin et al. (2014)).
• Ethical/off‑target caution: the authors correctly stress germline ethical concerns and off‑target risk, citing early human embryo work (Liang et al., 2015) that reported high off‑target and mosaicism, which reasonably supported conservative positions at the time (Liang et al. (2015)).

Critical appraisal — what the paper did well

1. Concise primer-level narrative that compiles representative seminal experiments across editing contexts (zygote, somatic in vivo, ex vivo iPSC/organoid corrections) with correct references to foundational studies (Khan & Ullah review (2021)).
2. Appropriate emphasis on off‑target specificity as a major barrier, aligning with community concerns and later methodological advances focused on improving HDR/NHEJ balance and guide design (O).

Major limitations, blindspots, and biases

• No systematic methods or PRISMA‑style search: the paper is a narrative review without described search terms, inclusion/exclusion criteria, or reference counts — this limits reproducibility and risks selection bias (Khan & Ullah review (2021) — methods missing).
• Literature coverage stops at ~2016: many transformative advances after 2016 (high‑fidelity Cas9 variants, base/prime editors, anti‑CRISPR tools, delivery systems) are absent, making the review dated for researchers seeking state‑of‑the‑art methods (Cas9‑DN1S (2019)).
• No quantitative/meta‑analytic synthesis: the paper does not extract effect sizes, frequencies, or cross‑study comparisons (e.g., HDR rates, off‑target rates), reducing utility for process design or risk assessment; modern systematic reviews (or data‑driven syntheses) provide greater decision value (Systems biotech review (2016)).
• Scant attention to manufacturing/CHO/host engineering literature: the paper focuses on therapeutic gene correction rather than CRISPR use to engineer production hosts (CHO, yeast, fungal, bacterial systems) for therapeutic protein manufacturing — a missed opportunity given CRISPR's major industrial role (CHO engineering meta-review (2026)).
• Insufficient discussion of delivery, immunogenicity, and regulatory pathway: delivery methods (AAV, LNP, RNP), immune responses to Cas proteins, and regulatory hurdles for therapeutic manufacturing and in vivo editing are only lightly mentioned.

Concrete recommendations for authors / readers

1. For a future revision: add a methods section (search strategy, databases, date range, inclusion/exclusion) and a table of included studies with extracted quantitative endpoints (HDR%, indel%, off‑target counts, delivery method)
2. Integrate post‑2016 advances: high‑fidelity Cas variants (e.g., eSpCas9, HiFi Cas9), base and prime editors, anti‑CRISPR proteins/delivery, and engineered Cas fusions that improve HDR/NHEJ balance (Anti‑CRISPR delivery (2025)).
3. To address protein production applications: include CRISPR use for host engineering (CHO knockouts/knockins, glycoengineering in yeast/fungi, secretion pathway optimization), with quantitative titer improvements and process-level considerations (Microbiome/synthetic biology review (2025), Recombinant DNA manufacturing review (2023)).

What would overturn my main critique?

If the authors provided an updated, transparent literature search and appended quantitative tables showing that (a) off‑target rates were systematically low across technologies and contexts, and (b) that CRISPR‑based host engineering produced robust, reproducible increases in therapeutic protein titers across multiple host systems, the review's current limitations would be substantially mitigated.

Short evidence list (selected citations used in this analysis)

• Jinek et al. (2012) — Cas9 programmable nuclease
• Wang et al. (2013) — zygote editing
• Yin et al. (2014) — in vivo somatic correction
• Liang et al. (2015) — human embryo editing concerns
• O